Kornimate/medical-research-clean huggingface dataset:
function integrity of neck anatomy in thyroid surgery

Conditions: Thyroid Carcinoma; Thyroid Nodule (Benign); Ablation; Retina

Summary: recent trends in the management of patients with low-risk papillary thyroid carcinoma who have a nonsuspicious or cytologically benign contralateral nodule call into question the need for routine total thyroidectomy. although the lobectomy for the unilateral thyroid cancer with contralateral benign nodules is sufficient treatment, some of the patients might suffer from the anxiety of the residual benign thyroid nodule and tend to choose total thyroidectomy, which might be overtreatment. thermal ablation has been proven to be effective in achieving nodule shrinkage and being also free from major complications. in our institution, intraoperative rfa was a proposed alternative strategy to treat the contralateral benign nodules after the thyroid lobectomy for the malignant lobe, which was found to have a better quality of life on anxiety, physiological health, social family, psychological and sensory mentions with a considerable complication rate.


Eligibility criteria:
inclusion criteria: * patients diagnosed with unilateral thyroid carcinoma and contralateral benign nodule confirmed by preoperative ultrasound-guided fine-needle aspiration cytology; * patients with contralateral nodules ≤ 20mm and located in the thyroid gland; * patients with clinical node-negative cervical compartment at palpation and neck ultrasound. exclusion criteria: * previous history of neck surgery * previous history of neck radiation therapy
a study of avastin (bevacizumab) in combination with platinum-based chemotherapy in patients with advanced or recurrent squamous non-small cell lung cancer

Conditions: Non-Small Cell Lung Cancer

Summary: this single arm study will assess the feasibility of using avastin plus platinum-based chemotherapy (cisplatin-gemcitabine or carboplatin-paclitaxel) in patients with advanced or recurrent squamous non-small cell lung cancer who have not received prior chemotherapy. patients will receive preventive radiation, followed by one cycle of chemotherapy alone and 5 cycles of chemotherapy in combination with avastin (15mg/kg iv on day 1 of each 3 weekly cycle), followed by avastin alone for a maximum total treatment period with avastin of 12 months. the anticipated time on study treatment is 3-12 months, and the target sample size is \<100 individuals.


Eligibility criteria:
inclusion criteria: * adult patients, \>=18 years of age; * documented squamous non-small cell lung cancer; * stage iiib with pleural or pericardial effusion, stage iv, or recurrent disease; * suitable for platinum-based treatment as first line chemotherapy. exclusion criteria: * prior systemic anti-tumor therapy; * prior radiotherapy for treatment of patient's current stage of disease; * other primary tumors within last 5 years, except for controlled limited basal cell or squamous cancer of the skin, or cancer in situ of the cervix; * major surgery, open biopsy or significant traumatic injury within 28 days prior to randomization.
study of asn51 in adults with early alzheimer's disease

Conditions: Alzheimer Disease

Summary: the main purpose of this study is to evaluate the safety, tolerability, and effect on biomarkers of disease pathophysiology and pathology, pharmacokinetics (pk), and preliminary effects on measures of clinical efficacy of multiple doses of asn51 in adult participants with early alzheimer's disease (ad).


Eligibility criteria:
key inclusion criteria: 1. male or female age 50 to 80 years. 2. a clinical diagnosis of alzheimer's disease (ad) at either the mild cognitive impairment or mild ad dementia stage per national institute on aging and the alzheimer's association, consistent with stage 3 and stage 4 in the food and drug administration (fda) draft guidance for early ad. 3. mini-mental state examination score of 20 to 28 (inclusive). 4. a plasma ptau217 result consistent with the presence of amyloid pathology. 5. must have a care partner who, in the investigator's judgment, has frequent and sufficient contact with the participant as to be able to provide accurate information about the participant's cognitive and functional abilities. the care partner must be literate and provide informed consent. key exclusion criteria: 1. any medical or neurological/neurodegenerative condition (other than ad) that, in the opinion of the investigator, might be a contributing cause to the participant's cognitive impairment (e.g., current history of substance abuse, uncontrolled vitamin b12 deficiency or abnormal thyroid function, stroke or other cerebrovascular condition, normal pressure hydrocephalus, parkinson's disease, lewy body dementia, cerebral amyloid angiopathy, frontotemporal dementia) or could lead to discontinuation, lack of compliance, interference with study assessments, or safety concerns. 2. non-amnestic presentation of ad as judged by the investigator. 3. woman of childbearing potential. 4. any prior or ongoing exposure to active or passive anti-amyloid immunotherapy, anti-tau immunotherapy, an anti-tau antisense oligonucleotide or gene therapy, or o-linked-β-n-acetylglucosaminidase (o-glcnacase) inhibitor. other protocol defined inclusion and exclusion criteria could apply.

Keywords: alzheimer's disease asn51
association of tissue oxygen saturation with postoperative acute kidney injury in double valves replacement surgery

Conditions: Acute Kidney Injury

Summary: to investigate the relationship of tissue oxygenation of different organs and tissue beds (e.g., a tissue bed on the arm vs. leg vs. flank tissue bed(s) and renal tissue bed, and thus can be used as a surrogate of renal tissue oxygenation monitoring.

in this study, we will monitor tissue oxygenation of four different tissue beds including cerebral tissue (scto2) on the forehead, and 3 somatic tissue beds monitored on the forearm (sarmo2), upper leg (slego2), and the renal region (srro2). the primary end point is aki and the secondary end points are postoperative major non-renal complications (e.g. stroke, delirium, myocardial infraction, heart failure, new or worsening arrhythmia, mechanical ventilation \> 24 hours, deep wound infection, etc.) and mortality. the associations between tissue oxygenation of different tissue beds, i.e. scto2, sarmo2, slego2, and srro2, and aki and non-renal outcomes will be compared to explore the tissue bed(s) whose oxygen saturation has a stronger association with the outcomes of interest. the strength of this study is to use the patient as self-control.

Eligibility criteria:
inclusion criteria: * written informed consent obtained * age ≥18 years of age * double valves replacement surgery with cardiopulmonary bypass (cpb) exclusion criteria: * the trauma, deformity or abnormality sites which the sensor will be put may affect the monitoring of the data * preoperative renal dysfunction needs renal replacement therapy * emergency surgery * preoperative intubated patient * unable to cooperate with the study, i.e., mental illness, et al * patients with hemoglobin and anemia * participate in other trials in the prior 3 months * patient refuses to participate in the study * patient is unfit for the study decided by reach stuff
highly selective cdk7 inhibitor q901 in selected advanced solid tumors

Conditions: Advanced Cancer; Metastatic Cancer

Summary: multicenter, open-label, dose-escalation, safety, tolerability, pk and pharmacodynamic study with a dose expansion at the rp2d to evaluate safety and potential antitumor activity of q901 as a monotherapy and in combination with pembrolizumab


Eligibility criteria:
inclusion criteria: * participants with histologically or cytologically confirmed advanced or metastatic ovarian, crpc, hr+ her2- breast, endometrial, colorectal, small-cell lung, or pancreatic cancer, who have progressed following standard-of-care therapy or for whom there is no standard therapy that confers clinical benefit * measurable disease per recist v 1.1 * ecog performance status 0,1 or 2 * life expectancy of at least 3 months * age ≥ 18 years * signed, written irb-approved informed consent form exclusion criteria: * new york heart association class iii or iv cardiac disease, or myocardial infarction, severe unstable angina, coronary/peripheral artery bypass graft, congestive heart failure within the past 6 months * have a corrected qt interval (using fridericia's correction formula) (qtcf) of \>470 msec (females) and \>450 msec (males) * active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy * active, poorly controlled autoimmune or inflammatory diseases
a study of bkm120 in adult japanese patients with advanced solid tumors

Conditions: Advanced Solid Tumor

Summary: in this study, bkm120 will be administered to adult patients with advanced solid tumors whose disease has progressed despite standard therapy or for whom no standard therapy exists. the trial will confirm the safety and tolerability and determine the maximum tolerated dose (mtd) of bkm120 in japanese patients.


Eligibility criteria:
inclusion criteria: 1. patients with histologically confirmed, advanced unresectable solid tumors who have progressed on (or not been able to tolerate) standard therapy or for whom no standard anticancer therapy exists. 2. at least one measurable or non-measurable lesion as defined by recist guidelines for solid tumors. 3. age ≥ 20 years 4. eastern cooperative oncology group performance status (ecog p.s.) of ≤ 2 5. life expectancy of ≥ 12 weeks 6. patients must have the laboratory values exclusion criteria: 1. patients with a history of primary central nervous system tumors or brain metastases or who have signs/symptoms attribute to brain metastases and have not been assessed with radiologic imaging to rule out the presence of brain metastases 2. prior treatment with a pi3k inhibitor 3. patients with any peripheral neuropathy ≥ ctcae grade 2 4. patients with unresolved diarrhea ≥ ctcae grade 2 5. women of child-bearing potential who are pregnant or breast feeding. men or women of reproductive potential not to sign informed consent for birth control. barrier contraceptives must be used throughout the trial and six months after the end of treatment. other protocol-defined inclusion/exclusion criteria may apply

Keywords: pi3k, advanced solid tumor
the effects of functional strengthening in spastic cerebral palsy

Conditions: Spastic Cerebral Palsy

Summary: functional strengthening exercises have been proven to be effective in patients with spastic cerebral palsy. however, which exercise is the most effective is unknown. the aim of this study is to examine the effectiveness of three different progressive functional exercise programs in children with unilateral and bilateral spastic cerebral palsy.

children with cerebral palsy have weakness in thier muscles due to cortical lesions leading to deficiencies in motor control, balance and functional abilities. all children with cerebral palsy have shown to present with foot and ankle disorders; the ankle dorsi and plantar flexor muscles are both problematic; the plantarflexors are usually spastic and the dorsiflexors are usually not active enough and usually these muscle problems lead to problems in the childrens' gait abilities. when rehabilitation programs are examined, the results of exercises addressing these problems do not have precise answers. functional strengthening exercises have been proven to be effective in patients with spastic cerebral palsy. however, which exercise is the most effective is unknown. which muscle goup has the most effect on gait, balance and functional activities is still unclear. therefore, the investigator's aim in planning this study is to examine the effectiveness of three progressive functional exercise programs in children with unilateral and bilateral spastic cerebral palsy.

Eligibility criteria:
inclusion criteria: * accepting to participate in the study, * being between 5-15 years old, * having a diagnosis of spastic cerebral palsy, * being level i-ii according to gmfcs, exclusion criteria: * having limited cooperation which prevents participation in the study, * refusing to participate in the study, * having an orthopedic disorder or systemic illness which prevents movement in the lower extremities, * having a botulinum toxin application in the last 3 months
the gd-2008 all protocol for childhood acute lymphoblastic leukemia

Conditions: Acute Lymphoblastic Leukemia

Summary: the guangdong work group of childhood acute lymphoblastic leukemia (all) therapy was set up in october 2002. the investigators treated the childhood all with a gz2002 protocol since the year 2002, and the protocol was mainly derived from the allic-bfm 2002 protocol. after summarizing the last six years' experience, our group revised the gz2002 all protocol in the year 2008, which is named gd-2008 all protocol. the diagnosis and classified criteria is according to the allic-bfm 2002 protocol, and the chemotherapy protocol consists all the therapeutic phases as the allic-bfm 2002 protocol prescribed.

the modification includes: 1. in the induction phase, the agent of dexamethasone 6 mg/m2 is used instead of prednisone after prednisone prophase. 2. the phase "cam" is 2 weeks for sr patients and 4 weeks for ir and hr patients,respectively. 3. both the sr and ir treatments involve the protocol mm /m (8 weeks) in the phase of consolidation. however, the folinic acid rescue starts at 36 hours instead of 42 hours. the type of hr enters the block treatment the same with the bfm protocol. 4. there is not randomized study in delayed intensification. the gd-2008 all protocol uses the same protocol ii with the bfm study. 5. the randomized study focus on the phase of maintenance. the maintenance a is the same with the bfm protocol, while the maintenance b consists of 6mp/mtx and vcr/ dexamethasone. the cycle is 8 weeks: vcr at d1, dexamethasone at d2 to d7, 6mp from d8 to d56, and mtx at d9,d16, d23, d30, d37,d44,d51. 6. the gd-2008 all protocol for hr patients use the re-blocks and protocol ii phases.

Eligibility criteria:
inclusion criteria: * cytologically proven acute lymphoblastic leukemia (all) * no relapse of a previously unrecognized all * patients must meet one of the following risk criteria: * standard-risk (sr) group meeting all of the following criteria: * blasts \< 1,000/μl in peripheral blood (pb) on day 8 * aged 1 to \< 6 years * initial wbc \< 20,000/μl * m1 (5%) or m2 (≥ 5% to \< 25%) blasts in bone marrow on day 15; * m1 marrow on day 33. * intermediate-risk (ir) group meeting all of the following criteria: * aged \< 1 or ≥ 6 years and/or wbc ≥ 20,000/μl * blasts \< 1,000/μl in pb on day 8 * m1 or m2 marrow on day 15 * m3 (≥ 25%) marrow on day 15 or meets sr criteria but m3 marrow on day 15 and \*m1 marrow on day 33. * high-risk (hr) group meeting ≥ 1 of the following criteria: * meets ir criteria and m3 marrow on day 15 (not sr and m3 on day 15) * blasts ≥ 1,000/μl in pb on day 8 * m2 or m3 marrow on day 33 * translocation t(9;22) \[bcr/abl+\] (philadelphia chromosome-positive) or t(4;11) \[mll/af4+\]. exclusion criteria: * no down syndrome * no other major disease that prohibits study treatment (e.g., severe congenital heart disease) * not requiring significant therapy modification owing to study therapy associated complications * no complications due to other interventions * no one with missing data that are needed for the differential diagnosis, or for selection of the proper therapy arm
primary care beverage study

Conditions: Obesity; Dental Caries

Summary: this is a pilot randomized clinical trial of a brief educational intervention offered in primary care for latino parents that promotes healthy beverage consumption by infants and toddlers. the control group will receive an educational intervention that promotes parents reading to children.

to use a randomized controlled trial (rct) design to test the efficacy of a primary care-based intervention to promote bright futures recommendations for consumption of sugar-sweetened beverages and 100% fruit juice among latino children ages 6 months to 5 years.

Eligibility criteria:
inclusion criteria: * parents self-identify as latino * parents speak english or spanish * parents have a child between the ages of 6 months and 5 years exclusion criteria: * parents who have participated in group educational sessions on nutrition offered through our obesity clinic or who have been newly referred to obesity clinic * parents whose child has a chronic condition which affects feeding (such as requiring tube feeds or being on a specialized diet for poor weight gain)

Keywords: dietary sucrose
efficacy of fluorescein visualization of the uterus in detecting endometrial cancer invasion

Conditions: Endometrial Cancer

Summary: to determine if fluorescein systemic injection during hysterectomy procedure can be useful in revealing the depth of endometrial cancer invasion.

all research participants will receive fluorescein injection through their existing intravenous line during their operative procedure for endometrial cancer staging. this will consist of one ampule (5 cc) injected intravenously prior to ligation of the uterine arteries. after the uterus is removed it will be sent to surgical pathology for evaluation as per routine care. the pathologist will open the uterus and evaluate the endometrium. he or she will then cut into the myometrium in an area most suspicious for invasion. the cross section of the myometrium and endometrium will be photographed while exposed to a woods lamp. the normal myometrium will have a yellow fluorescent appearance under the woods lamp. the cancerous tissue will have minimal fluorescence. the measurement will be taken estimating the depth of invasion of the cancer into the myometrium on the basis of its physical appearance under the woods lamp. cross-sectioning of the uterus is routine procedure by pathology for the intra-operative evaluation of endometrial cancer. this information routinely is provided in order to determine if lymph node staging is necessary. the area that was measured and photographed will then be prepared for a frozen section to document depth of invasion. this is the standard procedure performed during an endometrial staging. the depth of invasion on the frozen section will be recorded. this same area will undergo histologic confirmation by permanent pathology to determine depth of invasion. the frozen section is part of routine standard of care in evaluation of endometrial cancer.

Eligibility criteria:
inclusion criteria: * documented endometrial cancer and scheduled for hysterectomy as part of their treatment. * no known allergy to fluorescein dye * ability to understand and sign informed consent * 18 years of age or older exclusion criteria: * prior hysterectomy * known sensitivity to fluorescein dye
evaluate and compare the rate of para-stomal herniation after permanent stoma formation

Conditions: Hernia

Summary: this study is being done to evaluate the use of a material (alloderm collagen mesh) during the stomal formation operation (surgery that will create a mouth-like opening on the surface of the body to an internal organ). the main purpose of this research study is to see if using this material will lower the hernia rate compared to normal repair without this material. the secondary purpose is to evaluate if using this material will increase or decrease complication rates.

this study seeks to examine the ability of an implantable collagen matrix to reduce the incidence of parastomal hernia formation. patients will be randomized preoperatively by a computer generated random allocation to either receive collagen mesh at the time of stoma formation, or to have stoma formation without mesh. stomas without mesh will be made in the standard surgical fashion dictated by the type of stoma: ileostomy, colostomy, ileal conduit. patients randomized to receive mesh will undergo stoma formation in an identical fashion, and will have a 8 cm x 12cm piece of alloderm mesh placed as a tissue reinforcement at the stoma site and extending under the midline incision. patients will be followed with physical examinations at approximately 2weeks post-op, 3, 6, 9, 12, 24 months post-op, and will undergo ct scanning of the abdomen and pelvis at 12 and 24months to determine hernia occurrence.

Eligibility criteria:
inclusion criteria: 1. patients will be at least 18 years of age. 2. male or female (excluding pregnant females). 3. patients will require stoma formation. 4. patients with asa \< 3. 5. patients informed about the study, and will have read; understood and signed the patient informed consent and authorization to use their phi, as applicable. 6. patients will be willing and able to submit to postoperative follow-up evaluations. exclusion criteria: 1. patients that have had prior surgical treatment parastomal herniation. 2. patients that refuse stoma formation. 3. patients with asa \> 3. 4. patients who have certain metabolic conditions (e.g., chronic hepatic or renal disease). 5. patients with evidence of pre-existing systemic or local infections. 6. patients with wound-healing or autoimmune disorders. 7. patients who, in the surgeon's opinion, would have a difficult time comprehending or complying with the requirements of the study. 8. patients with any conditions that were not suspected preoperatively and are only discovered at the time of the operation.

Keywords: stoma, hernia, mesh
lois: long-term follow-up in insite/sifi

Conditions: Degenerative Sacroilitis; Sacroiliac Joint Disruption

Summary: the purpose of this study is to evaluate the long term safety and effectiveness of si joint fusion using the ifuse implant system in patients with degenerative sacroiliitis (ds) and/or sacroiliac joint disruptions (sd). study design: this study is extended follow-up from two ongoing multicenter prospective us clinical trials. all participants have already undergone the surgical procedure of interest (si joint fusion with ifuse implant system). the two ongoing trials are: * sifi:( sacroiliac joint fusion with ifuse implant system) a single-arm trial of patients with degenerative sacroiliitis or sacroiliac joint disruption who underwent ifuse placement, and * insite(investigation of sacroiliac fusion treatment): a randomized clinical trial of the same patient population who underwent either non-surgical treatment or ifuse placement


Eligibility criteria:
inclusion criteria: 1. patient enrolled and treated in sifi or patient initially randomized to ifuse and treated in insite. note: patient may be in the initial follow up period associated with sifi or insite at the same time they consent for this study and "extend" their post-operative follow up. 2. patient has signed study-specific lois informed consent form. 3. patient has the necessary mental capacity to participate and is physically able to comply with study protocol requirements. exclusion criteria: 1. treated with ifuse as a "crossover" in insite. 2. currently pregnant or planning pregnancy within 5 years of ifuse implant. 3. patient is a prisoner or a ward of the state. 4. known or suspected active drug or alcohol abuse. 5. inadequately treated psychiatric illness (e.g., schizophrenia, major depression, personality disorders) that could interfere with study participation. 6. unwilling to perform the long-term follow up requirements of this study. 7. patient has any condition that could substantially prevent long-term follow-up. 8. unwilling to return to site at pre-specified study visits.

Keywords: si joint si joint injury si joint treatment si joint inflammation si joint problems si joint symptoms hypermobile joint si joint arthritis si joint pain treatment inflamed si joint si joint sclerosis locked si joint si joint injuries si joint disease si joint infection sacroiliac joint pelvic pain sacroiliac joint arthritis treatment si joint pain si joint injections